Kronox Lab Sciences has scheduled its 17th Annual General Meeting for September 16, 2026. The meeting will be held via video conferencing to transact ordinary and special business items.

The Board of Directors proposes a final dividend of ₹0.50 per equity share for the financial year ended March 31, 2026 (FY26). Shareholders will also consider the reappointment of Mr. Jogindersingh Jaswal as a director.

Key Agenda Items

The notice outlines specific resolutions for shareholder approval during the virtual meeting:

• Adoption of the Audited Standalone Financial Statements for FY26.
• Declaration of the final dividend.
• Reappointment of Mr. Jogindersingh Jaswal, who retires by rotation.
• Ratification of remuneration for Cost Auditors M/s. Diwanji & Associates.

Director Reappointment Details

Mr. Jogindersingh Jaswal seeks reappointment after serving since November 18, 2008. He holds a 26.39% stake in the company and draws an annual remuneration of ₹132 lakh. His expertise covers production, quality control, and human resources.

Cost Auditor Remuneration

The Board recommends ratifying the appointment of M/s. Diwanji & Associates as Cost Auditors for FY27. The proposed remuneration is fixed at ₹90,000 per annum plus applicable taxes. No directors or key managerial personnel have any financial interest in this resolution.

Meeting Logistics

The meeting will commence at 11:00 am on September 16, 2026. Remote e-voting will be available from September 13 to September 15, 2026. The cut-off date for voting rights is September 9, 2026. Share transfer books will remain closed from September 10 to September 16, 2026.

Kronox Lab Sciences has fixed September 9, 2026, as the record date for determining shareholder eligibility for its final dividend of ₹0.50 per equity share for FY26.

The Vadodara-based specialty chemical manufacturer declared the dividend in May 2026, following a net profit increase of 8.6% to ₹276.6 crore for the financial year ended March 31, 2026. The company maintained revenue stability at ₹1,012.2 crore while expanding profitability through margin optimization.

Financial Performance

Revenue from operations remained largely flat at ₹1,012.2 crore, compared to ₹1,001.9 crore in FY25. Despite the modest top-line growth, the company delivered strong bottom-line results driven by operational efficiency.

Export revenue contributed significantly to the total turnover, rising to 32.4% of total revenue in FY26, up from 26.6% in the previous year. Foreign exchange earnings stood at ₹308.1 crore.

What the Numbers Show

The divergence between flat revenue growth and double-digit profit expansion highlights a shift in profit composition. Other income surged 105.6% to ₹51.9 crore, primarily driven by interest income which more than doubled to ₹36.8 crore. This non-operating contribution accounts for a substantial portion of the net profit growth, indicating that the bottom-line beat was partly fueled by higher returns on surplus cash rather than purely operational leverage.

Balance Sheet and Cash Flow

Kronox maintained a robust liquidity position with a current ratio of 7.60, up from 7.28 in FY25. Total equity increased to ₹1,161.3 crore from ₹901.1 crore. The company generated ₹238.9 crore from operating activities, though this was lower than the ₹307.0 crore recorded in FY25.

Capital expenditure remained active with cash outflows from investing activities totaling ₹238.2 crore. This included ₹33.1 crore on property, plant, and equipment purchases as the company prepares for its upcoming expansion at Dahej.

Strategic Outlook

Management highlighted progress on Unit IV at Dahej, noting that all necessary regulatory permissions, including environmental clearance, have been obtained. Construction is expected to commence shortly, with production targeted within the next two to three years. The new facility aims to diversify product offerings into derivatives such as acetate, citrate, and succinate.

Promoter holding remained unchanged at 74.18% as of March 31, 2026. The Board also recommended ratifying the remuneration of cost auditors M/s Diwanji & Associates for FY27.